The global palonosetron hydrochloride market is anticipated to grow at a CAGR of around 5.2% during the forecast period 2020 to 2027 and to reach around US$ 2.9 Bn by 2027.

Market Dynamics

Rapid advancements in drug discovery, high investment for drug development that lower the health effects of chemotherapy or post surgery, and players focus on introduction of innovative solutions are major factors expected to drive the growth of global palonosetron hydrochloride market. In addition, increasing government spending on development of healthcare infrastructure in order to enhance the R&D capabilities and developing medical regulatory scenario are among other factors expected to support the growth of palonosetron hydrochloride market.

Major players are focused on enhancing the business through strategic partnership and innovative product launches is expected to augment the growth of global market.

In 2014, the FDA approved ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to less than 17 years.

In 2018, Teva Pharmaceutical Industries Ltd. a globally operating pharmaceutical company launched a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States. The product launch is expected to help the company to enhance the business and strengthen company position in the US market.

In 2018, Helsinn Healthcare SA and Eisai Co., Ltd pharmaceutical companies operating on global level and focused on drug discovery and delivery revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise in order to promote and distribute ALOXI® (palonosetron HCl) injection. This agreement is expected to help the company to strengthen its position in the US market.

In 2018, Hikma Pharmaceuticals PLC a company that develops, manufactures, and markets pharmaceutical products across the globe launched Palonosetron Hydrochloride (HCl) Injection, 0.25mg/2mL. This product launch is expected to help the company to enhance the customer base.

In 2018, Dr. Reddy’s Laboratories Ltd. a leading multinational pharmaceutical company launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of ALOXI. This is expected to help the company to enhance the business.

However, factors such as side effects of medicine and strict government regulations related to product approval are expected to hamper the growth of global palonosetron hydrochloride market. In addition, high cost associated to R&D activities is expected to challenge the growth of palonosetron hydrochloride market.

High investment by major players and increasing public-private partnerships for introduction of innovative solutions are factors expected to create new opportunities for players operating in the palonosetron hydrochloride market over the forecast period. In addition, favorable business policies by the government of developing countries and emergence of small & mid-size enterprises with innovative solutions are factors expected to support the revenue transaction of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global market due to the increase in the number of cancer patients receiving chemotherapy. In addition, presence of large number of players operating in the country and focus on business expansion through acquisitions this is expected to support the growth of regional market.

Competitive Landscape                                                                                 

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market	Global Palonosetron Hydrochloride Market
Analysis Period	2016 – 2027
Base Year	2019
Forecast Data	2020 – 2027
Market Stratification	Route Of Administration, Distribution Channel and Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Palonosetron Hydrochloride Market Segment Analysis, 2019

The global palonosetron hydrochloride market is segmented into route of administration and distribution channel. The route of administration segment is divided into intravenous and oral. Among the route of administration, the intravenous segment is expected to account for significant revenue share in the target segment. The distribution channel segment is bifurcated into hospital pharmacies, online stores, drug stores, and retail stores.

The players profiled in the report are Merck, Wavelength, Farmihispania Group, ALP Pharm, Shanghai Jinhe Bio-Pharmaceutical Co. Ltd., Tecoland, Qilu Pharmaceutical, Teva API, Novartis, and Roche.

Market Segmentation

Market By Route Of Administration

Intravenous

Oral

Market By Distribution Channel

Hospital Pharmacies

Online Stores

Drug Stores

Retail Stores

Market By Region

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT